We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 50 → 0 (-50)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $94M → $0 (-$94M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 50

Holders
–
Holders Change
-50
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
50
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$12.7M
2
PC
Periscope Capital
Ontario, Canada
-$7.85M
3
Millennium Management
Millennium Management
New York
-$5.99M
4
Macquarie Group
Macquarie Group
Australia
-$5.09M
5
LA
Linden Advisors
New York
-$5.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCL
1
Glazer Capital LLC
New York
– -$12.7M -1,254,733 Closed
PC
2
Periscope Capital
Ontario, Canada
– -$7.85M -776,797 Closed
Millennium Management
3
Millennium Management
New York
– -$5.99M -593,018 Closed
Macquarie Group
4
Macquarie Group
Australia
– -$5.09M -504,000 Closed
LA
5
Linden Advisors
New York
– -$5.03M -498,000 Closed
Marshall Wace
6
Marshall Wace
United Kingdom
– -$4.59M -453,992 Closed
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
– -$4.13M -408,574 Closed
TCSAM
8
Tyrus Capital S.A.M.
Monaco
– -$4.04M -400,000 Closed
WP
9
Woodline Partners
California
– -$3.79M -375,000 Closed
SC
10
Sculptor Capital
New York
– -$3.56M -352,907 Closed
RCM
11
Radcliffe Capital Management
Pennsylvania
– -$3.12M -308,841 Closed
PMAM
12
Picton Mahoney Asset Management
Ontario, Canada
– -$2.78M -274,995 Closed
Bank of America
13
Bank of America
North Carolina
– -$2.63M -260,000 Closed
FTCM
14
First Trust Capital Management
Illinois
– -$2.59M -256,426 Closed
MI
15
MMCAP International
Cayman Islands
– -$2.52M -250,000 Closed
MF
16
Magnetar Financial
Illinois
– -$2.33M -231,100 Closed
AA
17
AQR Arbitrage
Connecticut
– -$2.02M -200,208 Closed
KL
18
KIM LLC
Kansas
– -$2.02M -200,000 Closed
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
– -$1.51M -150,000 Closed
MCM
20
Moore Capital Management
New York
– -$1.26M -125,000 Closed
FTCM
21
Fir Tree Capital Management
New York
– -$1.07M -106,300 Closed
State of Wisconsin Investment Board
22
State of Wisconsin Investment Board
Wisconsin
– -$1.02M -100,825 Closed
MTCM
23
Mint Tower Capital Management
Netherlands
– -$1.01M -100,000 Closed
TCM
24
Tenor Capital Management
New York
– -$1.01M -100,000 Closed
Hudson Bay Capital Management
25
Hudson Bay Capital Management
Connecticut
– -$1.01M -99,999 Closed
1
2

EBAC Hedge Fund Activity: Q1 2023 in Review

0 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q1 2023, worth a combined $0 — down 100% from $94M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of EBAC and 0 opened new positions — a net loss of 50 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Glazer Capital LLC, exiting entirely with an estimated $12.7M sold.

  • 0 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q1 2023, down from 50 in Q4 2022.
  • Funds reported $0 of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q1 2023 and 50 closed out, a net change of -50 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q1 2023 was Glazer Capital LLC, an estimated $12.7M sold.

Based on aggregated 13F filings for Q1 2023.